Radiation Oncology – Theragenics

radiation oncology

An industry pioneer and leader, Theragenics has an unparalleled history of more than 35 years in the manufacture, global supply and distribution of low-dose rate (LDR) brachytherapy seeds for the treatment of prostate cancer, intra-ocular malignancies, and other tumor types with radiosensitivity. We continue to invest and develop innovative brachytherapy solutions to better serve physicians and their patients.

Content intended for the USA. Indications may vary in different countries; please either consult the appropriate IFU or your local distributor.

radiation oncology

Unequaled commitment to brachytherapy and the safe and effective treatment of patients worldwide.

Trusted Experience and Quality

We are a dedicated and loyal partner to 1) physicians & their patients, 2) medical physicists, nurses, and administrators, 3) academic & community institutions, and 4) our valued distributors outside the USA.

Product Categories

A diverse range of brachytherapy seed products and accessories to support your implant needs.

Brachytherapy Seeds

Indicated to treat localized, unresectable tumors with low to moderate radio sensitivity. Tumors may be recurrent or residual following external beam radiation or excision of primary tumor.

Learn More

Prostate Implant Stranded Options

Pre-loaded needle kits and Real-Time intraoperative planning options.

Learn More

Prostate Implant Seed Cartridges

Seed Cartridge options are compatible with a traditional applicator implant technique.

Learn More

High Activity Seeds & Ocular Seed Carriers

Temporary implantation for the treatment of intra-ocular malignancies and other tumors types with radiosensitivity.

Learn More

Gold Fiducial Markers

Gold Markers for positional verification for Image Guided Radiation Therapy.

Learn More

Content intended for the USA. Indications may vary in different countries; please either consult the appropriate IFU or your local distributor.

Resources

American Cancer Society

Other than skin cancer, prostate cancer is the most common cancer in American men. The American Cancer Society’s estimates for prostate cancer in the United States for 2021 are:

About 248,530 new cases of prostate cancer
About 34,130 deaths from prostate cancer

American Brachytherapy Society

The American Brachytherapy Society finds many men diagnosed with prostate cancer are not presented with a highly effective, minimally invasive treatment option: prostate brachytherapy seed implants.

Prostate brachytherapy seed implants, also known as low-dose-rate brachytherapy (LDR-BT) is a highly effective, minimally invasive treatment for organ-confined prostate cancer. It can be offered as a single treatment for low-risk disease or in conjunction with external beam radiotherapy (EBRT) and/or androgen-deprivation therapy (ADT) for intermediate and high-risk disease.

Prostate Cancer Free Foundation

The Prostate Cancer Free Foundation, formerly the Prostate Cancer Treatment Research Foundation, was established in November of 2010. The Foundation works to help people interested in and affected by prostate cancer through education and research. This research is supported by the members of the Prostate Cancer Results Study Group, an international team of experts in the field of prostate cancer.